Arecor Therapeutics PLC ARECOR TO HOST KOL WEBINAR
19 May 2022 - 01:02AM
RNS Non-Regulatory
TIDMAREC
Arecor Therapeutics PLC
18 May 2022
Arecor Therapeutics plc
("Arecor" or the "Group")
ARECOR TO HOST KOL WEBINAR ON THE NEED FOR CONCENTRATED AND
RAPID ACTING INSULIN TREATMENTS IN DIABETES CARE
Cambridge, UK, 18 May 2022: Arecor Therapeutics plc (AIM: AREC),
the biopharmaceutical group advancing today's therapies to enable
healthier lives, today announces that it will host a key opinion
leader webinar entitled "The Need for Concentrated and Rapid Acting
Insulin Treatments in Diabetes Care", on Thursday 26 May, 2022, at
15:00-16:30 BST.
The virtual event will explore the treatment challenges for the
growing number of people living with diabetes, particularly those
with type 2 diabetes, who require high daily doses of insulin to
maintain their blood glucose within their target range. While rapid
acting insulins have become standard of care, there are currently
no concentrated rapid acting insulin products available to patients
to enable reduced injection volumes, fewer injections per day and
the potential for improved blood glucose control.
Arecor is developing a novel insulin product candidate, AT278,
which uniquely combines two key characteristics: an ultra-rapid
onset of action which is critical for postprandial glucose control
and an ultra-concentrated formulation to enable reduced injection
volumes and fewer injections per day. Data from a Phase I clinical
trial of AT278, recently presented at the 15(th) International
Advanced Technologies and Treatments for Diabetes (ATTD) meeting,
showed that AT278 exhibited an accelerated pharmacokinetic (PK) and
pharmacodynamic (PD) profile when compared to NovoRapid(R), a gold
standard prandial insulin treatment, despite a 5-fold increase in
concentration.
Arecor's webinar will bring together four world-class experts in
the field of diabetes care, who will discuss the AT278 clinical
data as well as the clinical and patient need. The event will be
moderated by Jay Skyler, Professor of Medicine, Pediatrics &
Psychology, in the Division of Endocrinology Diabetes &
Metabolism at the University of Miami, USA.
-- Wendy Lane, Clinical Endocrinologist, Director of Clinical
Research, Mountain Diabetes and Endocrine Center, Asheville, USA,
will discuss the increasing need for rapid-acting concentrated
insulin products for people living with Type 2 diabetes from a
clinical perspective.
-- Davida Kruger, Certified Diabetes Nurse Practitioner, Henry
Ford Health System, Division of Endocrinology, Detroit, USA, will
focus on the benefits of concentrated insulin from the patient
perspective.
-- Thomas Pieber, Head of the Division of Endocrinology and
Metabolism at the Medical University of Graz, Austria, will
summarise the results from Arecor's Phase I clinical trial of its
ultra-rapid, ultra-concentrated insulin product candidate,
AT278.
The presentations will be followed by a live Q&A
session.
To register for the event on the Advanced Technologies &
Treatment for Diabetes (ATTD) Educational Portal click here .
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD Tel: +44 (0) 20 7886 2500
and Broker)
Freddy Crossley, Emma Earl (Corporate
Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Angela Tel: +44 (0) 20 3709 5700
Gray Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
company transforming patient care by bringing innovative medicines
to market through the enhancement of existing therapeutic products.
By applying our innovative proprietary formulation technology
platform, Arestat(TM), we are developing an internal portfolio of
proprietary products in diabetes and other indications, as well as
working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The
Arestat(TM) platform is supported by an extensive patent
portfolio.
For further details please see our website, www.arecor.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABRGDUCBBDGDR
(END) Dow Jones Newswires
May 18, 2022 11:02 ET (15:02 GMT)
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Feb 2024 to Mar 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Mar 2023 to Mar 2024